IRF6 and metabolic dysfunction-associated steatotic liver disease: In the HFD-induced NAFLD model, hepatic IRF6 was inhibited by promoter hypermethylation, and hepatocyte-specific transgenic mice overexpressing IRF6 exhibited attenuated steatosis and metabolic disease.